Kane Biotech Inc. (KNE.V)
- GlobeNewswire
Kane Biotech to Release First Quarter 2022 Financial Results on May 26 – Conference Call to Follow
WINNIPEG, Manitoba, May 19, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2022 financial results after market close on Thursday, May 26, 2022. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and discuss
- GlobeNewswire
Kane Biotech Obtains ISO 13485 Certification
The quality management system of Kane is certified for design and development of medical devicesWINNIPEG, Manitoba, May 18, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today that it has obtained ISO 13485:2016 certification for its quality management system specific to its ongoing efforts to design and develop novel medical devices for the wound care market. “Quality and continuous improvement are core values of Kane and of pa
- GlobeNewswire
Kane Biotech Announces Closing of Private Placement
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 17, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) is pleased to announce that it has closed its non-brokered private placement offering (the “Offering”) announced previously on March 15, 2022, and has issued 10,000,000 common shares of the Company ("Common Shares") at a price of $0.10 per Common Share to raise gross proceeds of $1,000,000. Presi
